CD47 targeted therapies for the treatment of infectious disease
Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
1. A method of treating a subject for an intracellular pathogen infection with a hepadna virus, the method comprising:
administering to the subject an anti-CD47 agent that reduces the binding of CD47 on a hepadna virus infected cell, to SIRPα on a phagocytic cell, at an effective dose for increasing the phagocytosis of the hepadna virus infected cell.
2. The method of claim 1 , wherein the subject is a mammal.
3. The method of claim 2 , wherein the subject is a human.
4. The method of claim 1 wherein the pathogen is hepatitis B virus.
5. The method of claim 1 , wherein the subject has been previously diagnosed as having the intracellular pathogen infection.
6. The method of claim 1 , further comprising the step of monitoring the subject for clinical signs of infection or for presence of the hepadna virus following administration of the anti-CD47 agent.
7. The method of claim 1 , wherein the anti-CD47 agent specifically binds CD47.
8. The method of claim 7 , wherein the anti-CD47 agent is an antibody.
9. The method of claim 8 , wherein the antibody is humanized 5F9-hIgG4.
10. The method of claim 7 , wherein the anti-CD47 agent is a high affinity SIRPα reagent.
11. The method of claim 1 , wherein the anti-CD47 agent specifically binds SIRPα.
12. The method of claim 11 , wherein the anti-CD47 agent is an anti-SIRPα antibody that does not stimulate signaling through SIRPα.
13. The method of claim 11 , wherein the anti-CD47 agent is a soluble CD47 polypeptide that does not stimulate signaling through SIRPα.